Vir Biotechnology, Inc. (VIR)
Stock Price:
$41.02 USD
0.70 (1.74%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
4.84B |
| Revenue (ttm) |
10.15M |
| Net Income (ttm) |
n/a |
| Shares Out |
117.90M |
| EPS (ttm) |
-14.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 6, 2020 |
| Last Price |
$41.02 |
| Previous Close |
$40.32 |
| Change ($) |
0.70 |
| Change (%) |
1.74% |
| Day's Open |
38.80 |
| Day's Range |
38.72 - 41.38 |
| Day's Volume |
992,997 |
| 52-Week Range |
11.65 - 75.00 |
More Stats
| Market Cap |
4.84B |
| Enterprise Value |
4.49B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
117.90M |
| Float |
50.32M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-14.64 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.79M |
| Short Ratio |
1.67 |
| Short % of Float |
5.09% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
476.58 |
| PB Ratio |
13.98 |
| Revenue |
10.15M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
351.18M |
| Net Cash / Share |
2.98 |
| Gross Margin |
-1,330.12% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-28.60% |
| ROE |
-87.32% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
1 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$32.50*
(-20.77% downside)
Low
17.0
Current: 41.02
High
44.0
Target: 32.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 8.09 | 10.67 | 2.71 |
| Revenue Growth | -24.16% | 293.94% | - |
| Gross Profit | 8.09 | 10.67 | 2.71 |
| Operating Income | -178 | -119 | -81.50 |
| Net Income | -175 | -116 | -69.85 |
| Shares Outstanding | 30.35 | 7.67 | 2.15 |
| Earnings Per Share | -5.76 | -15.12 | -32.45 |
| Operating Cash Flow | -130 | -94.10 | -66.38 |
| Capital Expenditures | -8.94 | -8.17 | -2.74 |
| Free Cash Flow | -139 | -102 | -69.12 |
| Cash & Equivalents | 390 | 109 | 188 |
| Net Cash / Debt | 390 | 109 | 188 |
| Assets | 512 | 192 | 252 |
| Liabilities | 88.13 | 61.64 | 27.96 |
| Book Value | 424 | -179 | -68.92 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Vir Biotechnology, Inc. |
| Country |
United States |
| Employees |
237 |
| CEO |
George A. Scangos |
Stock Information
| Ticker Symbol |
VIR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VIR |
Description
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.